Aim: This study was designed to capture patient preferences for different aspects of asthma treatment from people with asthma in the UK, the Netherlands and Spain.
Introduction
The Global Initiative for Asthma (GINA) has produced guidelines for the management of asthma, 1 and these guidelines are updated annually and revised to reflect developments in the evidence base. The GINA guidelines describe the aim of asthma management as being the achievement and maintenance of asthma control. They highlight a number of aspects of asthma management; however, they do not account for those aspects which are most important to patients. European surveys indicate that few patients achieve guideline-defined asthma control. 2, 3 Consequently, asthma remains a significant burden, 4 is a leading cause of lost school and work days, 5 and has a significant impact on health-related quality of life. 6 Systematic attempts to understand the preferences of asthma patients have been reported previously. Osman et al reported that asthma patients were willing to trade higher levels of wheeze and sleep disturbance in order to avoid cough and breathlessness. 7 Zillich et al reported that patients with the greatest burden of asthma (as measured by quality of life questionnaires) were willing to pay the most for a hypothetical asthma 'cure'; 8 participants classified as mild were willing to pay $US48 per month, whereas participants who were classified as severe were willing to pay $US241 per month. Johannsson et al explored asthma patients' preferences for the type of maintenance treatment, number of inhalers, speed and duration of symptom relief, and symptom-free days (SFDs). 9 The number of SFDs was the most important attribute for patients; 85% of patients preferred an alternative treatment over their current treatment and were prepared to pay extra for it -but the analyses did not indicate reliably participants' willingness to pay for improvements. Most recently, King et al 10 reported a 242 study which embedded a discrete choice experiment (DCE) survey within a clinical trial of asthma patients. This study found that most respondents chose to continue with their current drug in most choice situations but this tendency differed depending on which medication they had been allocated. Participants valued being able to participate in usual daily activities and sport, and preferred minimal symptoms. This was a relatively small survey of 52 people which may explain why not all attributes emerged as predictors of choice. Some information has emerged from the literature regarding the importance of different aspects of asthma therapy, and the attributes of asthma therapy included in this study were derived directly from asthma patients and reflect recommendations in the GINA guidelines.
This study was designed to address some of the shortcomings of previous studies and to advance our understanding of patient preferences for asthma therapy; in particular, we have been able to estimate the monetary value placed on achieving better asthma control. In doing so, the strength of preference for alternative attributes of asthma management may be successfully quantified. There are an increasing number of papers in the literature on the methodology required to estimate patients' willingness to pay within discrete choice experiments.
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Methods
A stated preference DCE was designed to elicit patient preferences for different aspects of asthma therapy. The main aim of the study was to determine patients' strength of preference for control over their asthma.
Study measures
Discrete choice experiments (DCE) are a form of survey methodology which are widely used in health care to elicit the preferences of patients. 22, 23 The method characterises treatment interventions in terms of distinct attributes and levels (e.g. number of days with symptoms per week). 24 DCE methods can also be used to estimate the marginal value, in terms of willingness to pay out of one's own pocket, for different aspects of asthma therapy. 12 Respondents decide which combination of attributes and levels they prefer. Through a series of questions it is possible to establish the relative importance of attributes and the trade-offs that people are willing to make. This method was used to understand the value of the attributes of treatments for asthma.
Development work
Several phases of pilot work were undertaken. A draft list of ten attributes was developed through discussion with the study team including clinical experts. Ten attributes were considered to be too many to include in a survey because it would make decision-making very complex for study participants. Therefore, attributes that could not be related back to GINA guidelines, or purely clinical attributes such as FEV 1 which are less meaningful for patients, were dropped from the list. Two focus groups were conducted (in the UK and The Netherlands) to discuss the draft attributes and levels.
The final list of asthma attributes that were selected You will have asthma attacks occasionally in the next year, which are bad enough that you will need to see your GP or visit the A&E department at the hospital
Side effects
Your chance of suffering a side effect with this medication is very low (1 in a 100 or 1%)
Your chance of suffering a side effect with this medication is low (1 in 10 or 10%) Your chance of suffering a side effect with this medication is moderate (1 in a 5 or 20%)
Inhalers
You require preventer treatment with one inhaler only You require preventer treatment with two inhalers Copyright GPIAG -Reproduction prohibited http://www.thepcrj.org
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Patient preferences for asthma therapy:a discrete choice experiment 243 included: number of days per week with symptoms; number of days per week you require reliever medication; severity of asthma attacks/exacerbations; risk of mild side effects (described as cough, tremor etc); number of preventer inhalers required, and out of pocket cost (see Box 1 for a description of the attributes and levels). The cost attribute is included in order to estimate willingness to pay for improvements in the other attributes. The UK cost attribute levels and household income levels were converted to equivalent Dutch-and Spanish-specific Euro (€) rates using a purchasing power parity (PPP) calculation. Each attribute in the survey was described in two to three sentences and each attribute level was presented. The respondents were given pairwise choices based on an orthogonal design with foldover (as recommended by Louviere et al 24 ) to ensure no overlap. This resulted in 21 choices, 18 from the orthogonal matrix plus 3 reliability and consistency checks.
The attributes and levels were combined into choice sets using an orthogonal design (http://www.research.att.com/ njas/oadir/#3_2). Participants were presented with pairs of hypothetical treatments which described a specific level on each attribute, and were asked to state which they preferred ( Figure 1 ). The DCE questionnaire also included questions regarding socio-demographics, income, some clinical information such as medication, and the mini-Asthma Quality of Life Questionnaire. 25 The whole survey included the same 21 choice pairs, took about 30 minutes to complete, and participants were paid a nominal amount for taking part.
Pilot studies
Four asthma patients completed the survey in a 'think aloud' exercise, followed by a cognitive debrief interview to identify areas of misunderstanding. 26 In addition, in a second pilot study, 31 asthma patients completed the draft survey and data were analysed to determine if attribute coefficients were all in the anticipated direction. No problems other than a few minor wording changes emerged from these pilot studies.
Main study
The main study was conducted at sites in The Netherlands, Spain and the UK. Rigorous translations of the questionnaires were produced using standardised methods for the translation of patient-reported outcomes. 27 The UK cost attribute levels and household income levels were converted to equivalent Dutch-and Spanish-specific Euro (€) rates using a purchasing power parity (PPP) calculation. This means that the results from each country are completely comparable in monetary terms.
Different approaches to recruitment were adopted in each country, which ensured a representative broad sample of patients with mainly mild-to-moderate asthma. In the UK study, participants were recruited via newspaper advertisements using a telephone screener (developed with a clinician) prior to being invited to take part. In The Netherlands, patients were recruited through GP practices (n=124), respiratory specialist outpatient clinics (n=87) and through a Dutch patient advocacy group "Astma Fonds" (n=58). In Spain, asthma patients were recruited through six pneumonologists' outpatient clinics. Patients signed an informed consent before answering the questionnaire.
To be eligible, participants had to have a diagnosis of asthma, be 18 to 75 years old, be able to read and understand English, Spanish or Dutch as appropriate, be willing and able to give informed consent, and had to pass the telephone screener questionnaire (UK only).
Analysis
Each choice that a respondent made was analysed as a data point. The DCE data were analysed using the random effects probit model in LIMDEP 28 which accounts for multiple observations from the same individual. The choice responses were binary data and the regression model examined the extent to which each attribute predicted individuals' choices. From this analysis, willingness to pay for all attributes is estimated by taking the marginal rates of substitution between the attribute 'monthly cost of the drug' and the remaining attributes. Wald tests were used to test for differences in income subgroups.
Results
The characteristics of the study samples were summarised (Tables 1 & 2 dataset because they did not meet study entry criteria (they were all under 18 years old). The majority of patients had evidence of persistent asthma as shown by the large proportion using combination inhalers (long acting betaagonist plus inhaled corticosteroids, 55%) or inhaled corticosteroids alone (82%).
Choice data
Analysis of the choice data indicated that people were consistent (93.4% to 95.3%) and reliable (78.2% and 81.4%) in their answers to questions. All of the attributes were significant predictors of choice, indicating that participants valued all of them in their choices (Table 3) . Participants were willing to pay the highest amounts to avoid asthma attacks that required emergency medical care (€109.48) and to avoid days with asthma symptoms (€35.26 per day). Participants were willing to pay €15.74 to avoid a self-managed asthma attack which was higher than the willingness to pay to reduce days needing reliever medication or risk of side effects. In contrast, participants were not willing to pay very much to avoid commonly-encountered mild side effects (the side effect attribute was not designed to capture preferences around the more severe side effects that can occur with preventer inhalers).
Modelling improvements in asthma
The willingness-to-pay data allows for the estimation of how much patients value overall improvements in different aspects Copyright GPIAG -Reproduction prohibited http://www.thepcrj.org
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Patient preferences for asthma therapy:a discrete choice experiment 245 of their asthma. This is referred to as a 'welfare shift'. The value of moving to a total absence of asthma symptoms was estimated. The participants' current profile (described in terms of our attributes and levels) was used as one starting point, in addition to a hypothetical poorly-controlled state. The hypothetical poor asthma state was defined as five days per week with symptoms, five days per week needing reliever medication, side effects on 1% of days, one preventer inhaler, and an asthma attack that required an emergency visit to their doctor or hospital in the last twelve months. The willingness-to-pay amounts are estimated by simply determining the sum of the product of the attribute level shift (e.g. 5 days with symptoms to 0 days) and the willingness-topay value for a unit of that attribute. The analysis indicates that asthma patients were willing to pay €94. 16 Copyright GPIAG -Reproduction prohibited http://www.thepcrj.org C o p y r i g h t G e n e r a l P r a c t i c e A i r w a y s G r o u p R e p r o d u c t i o n P r o h i b i t e d
(described in terms of the attributes) to a total absence of asthma. Participants were willing to pay €78.42 per month to shift from their current asthma state to full control of asthma, and €305.53 per month to move from the hypothesised poor asthma state to full control of asthma (Table 4) . Wald tests revealed no statistically significant differences in the interacted coefficients based on low and high income.
Discussion
Summary of main findings
This study has collected patient preference data for asthma symptoms and therapy. People with asthma in three European countries all completed equivalent versions of a DCE survey. The DCE included five asthma-related attributes offset by the out-of-pocket cost attribute. These included number of days per week with symptoms, need for reliever medication, chance of mild side effects of preventer therapy (e.g. cough, tremor), number of preventer inhalers, and asthma attacks which either did or didn't require an unscheduled visit to a doctor or A&E. The DCE captured patient preferences for these attributes; this was expressed in terms of willingness-topay values. The results from the three countries in terms of the relative importance of the attributes were very similar. All of the attributes were significant predictors of choice, indicating that we were capturing patient preferences. The willingness-to-pay data indicated that the most important attribute was severe asthma attacks that required emergency visit to a GP or the hospital. Participants were willing to pay €109 per month to avoid this. The second most important attribute was the number of days per week with symptoms. This mirrors the findings from Johansson et al who reported that the number of symptom-free days per month was the most important attribute (their study did not include exacerbations). 9 In contrast, some of the other attributes were much less important to participants. Participants were only willing to pay an extra €3.95 per month to reduce their need for reliever medication, which supports the view that people are quite comfortable relying on their short-acting betaagonist medication. Willingness to pay to avoid self-managed exacerbations was also quite low at only €15.74 per month. Participants were willing to pay even less to reduce their risk of mild side effects such as cough, tremor and palpitations (this didn't include the more severe side effects that can occur less commonly). The relative unimportance of side effects is not a general finding in DCE studies. In our previous work, we identified that people with epilepsy placed much greater importance on the avoidance of side effects than they did on improving their seizure control. 29 This indicates that findings of these surveys could be disease-specific.
Strengths and limitations of this study
The study was designed as a European survey in an attempt to capture a broad scope of patient preferences. In addition, however, the three countries chosen have different systems in place for the payment of medication. Spain operates a co-pay system whereby the amount a patient pays depends on the price of the drug. In the UK, patients pay a set prescription fee regardless of drug price, and in the Netherlands patients pay nothing directly for their drugs. Participants in Spain were, on average, willing to pay more for their asthma medication than participants in the UK or Netherlands. The basic pattern of results in terms of the importance of the attributes compared to each other is similar for the three countries. The Spanish participants may have been willing to pay more because they are used to paying more for medication and implicitly better understand the concept that drug quality and price may be related. Alternatively, the results may reflect the mix of patients from each country. The different recruitment methods led to some variability, but also ensured that a wide range of patients were recruited into the study.
The study data were used to understand the value that people placed on improvements in their asthma. Participants' willingness to pay for moving from the sample average to a total absence of asthma symptoms was estimated. Assuming the median health state, participants were willing to pay €94 per month to move to a total absence of asthma. To shift from a hypothetical profile of poorly-controlled asthma to a total absence of asthma, participants were willing to pay €305 per month. Potentially any health state which can be described by the study attributes could be modelled in this way. It would also be possible to estimate the perceived benefits of new interventions, or even changes in clinical guidelines.
There are limitations with this study that should be noted. It is necessary to restrict the number of attributes that are included, and the choice of which to include is of course subject to bias. This means that we don't capture preferences for all aspects of asthma therapy, but just for our chosen attributes. We have tried to select attributes in an unbiased way, but there may well be other important aspects of asthma therapy that have not been included.
One other limitation of this research relates to the assumptions that are made about how people make decisions in a DCE. It is assumed that people trade between all of the attributes in the choice sets when making decisions, but such a complex approach to decision-making is not really consistent with evidence from cognitive psychology 30 . Due to the method required to elicit willingness-to-pay using marginal rates of substitution, a compensatory decision-making structure has to be assumed. In that respect, this study is the same as almost all other DCE studies in the literature. Some work has explored this issue but it remains unclear exactly how you could test for non-compensatory decision-making. 31, 32 What may appear to be compensatory decision-making at the aggregate level may
